Peripheral arterial disease

Lancet

Volumn 358, Issue 9289, 2001, Pages 1257-1264

  Ouriel, Kenneth ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BUFLOMEDIL; CILOSTAZOL; CLOPIDOGREL; HEPARIN; ILOPROST; LIPID; NAFTIDROFURYL; PENTOXIFYLLINE; PLACEBO; PROSTAGLANDIN E1; VASCULOTROPIN;

ARTERY DISEASE; BLOOD PRESSURE REGULATION; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; CORONARY ARTERY ATHEROSCLEROSIS; DIARRHEA; DISEASE ASSOCIATION; EXERCISE; GANGRENE; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; HYPERBARIC OXYGEN; INTERMETHOD COMPARISON; INTERMITTENT CLAUDICATION; LEG AMPUTATION; LEG PAIN; LEG REVASCULARIZATION; LEG ULCER; LIMB DISEASE; LIPID BLOOD LEVEL; MOBILIZATION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIMARY PREVENTION; PRIORITY JOURNAL; RISK ASSESSMENT; SMOKING CESSATION; STENT;

EID: 0035856220     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(01)06351-6     Document Type: Conference Paper

References (96)

1. Amputation rates as a measure of vascular surgical results
2. Defining the outcome of critical ischaemia: A one year prospective study
3. Long-term mortality and its predictors in patients with critical leg ischemia
4. Effect of diagnostic criteria on the prevalence of peripheral arterial disease
5. The prevalence of asymptomatic and unrecognized peripheral arterial occlusive disease
6. Prevalence in general practice
7. Peripheral arterial disease in the elderly: The Rotterdam Study
8. Mortality over a period of ten years in patients with peripheral arterial disease
9. Klinische beiträge zur pathologie des intermittierenden hinkens
10. Update on some epidemiological features of intermittent claudication
11. Peripheral arterial disease: Consequences for survival and association with risk factors in the Speedwell prospective heart disease study
12. A marked decline in the prevalence and incidence of intermittent claudication in Icelandic men 1968-1986: A strong relationship to smoking and serum cholesterol - The Reykjavik Study
13. Smoking, lipids, glucose intolerance and blood pressure as risk factors for peripheral atherosclerosis compared with ischemic heart disease in the Edinburgh Artery Study
14. Arteriopatia asintomatica degli arti inferiori. Prevalenza e fattori di rischio in una popolazione del sud Italia
15. A prospective study of peripheral occlusive arterial disease in diabetes. III: Initial lipid and lipoprotein findings
16. Intermittent claudication: Incidence in the Framingham study
17. The influence of smoking cessation and hypertriglyceridaemia on the progression of peripheral arterial disease and the onset of critical ischaemia
18. Lipoprotein (a) and its relationship to risk factors and severity of atherosclerotic peripheral vascular disease
19. Hyperhomocystinaemia: An independent risk factor for vascular disease
20. Update on fibrinogen as a cardiovascular risk factor
21. Evaluation of the coagulation and fibrinolytic systems in men with intermittent claudication
22. The Basle longitudinal study; report on the relation of initial glucose level to baseline ECG abnormalities, peripheral artery disease, and subsequent mortality
23. A randomised, blinded trial of clopidogel versus aspirin in patients at risk of ischaemic events (CAPRIE)
24. Morbidity and mortality in hypertensive adults with low ankle-arm blood pressure index
25. Natural history of arteriosclerosis of the lower extremities
26. Management of peripheral arterial disease
27. Long-term mortality and its predictors in patients with critical leg ischemia
28. Arteriosclerosis obliterans: Review of 520 cases with special reference to pathogenic and prognostic factors
29. Coronary artery disease in peripheral vascular patients: A classification of 1000 coronary angiograms and results of surgical management
30. Ankle-arm index as a predictor of cardiovascular disease and mortality in the Cardiovascular Health Study
31. Changing concepts of atherogenesis
32. Special communication the critical role of mechanical forces in blood vessel development, physiology and pathology
33. Structural identification by mass spectrometry of oxidized phospholipids in minimally oxidized low density liproprotein that induce monocyte/endothelial interactions and evidence for their presence in vivo
34. Biomechanical activation: An emerging paradigm in endothelia adhesion biology
35. Decreased basal nitric oxide release in hypercholesterolemia increases neutrophil adherence to rabbit coronary artery endothelium
36. Coronary plaque disruption
37. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology
38. Expression of the elastolytic cathepsins S and K in human atheroma and regulation of their production in smooth muscle cells
39. Apoptosis of vascular smooth muscle cells induced by in vitro stimulation with interferon-gamma, tumor necrosis factor-alpha, and interleukin-1-beta
40. Chlamydia linked to atherosclerosis
41. Chlamydia pneumoniae infection of vascular smooth muscle and endothelial cells activates NF-[kappa]B and induces tissue factor and PAI-1 expression: A potential link to accelerated arteriosclerosis
42. Doppler ankle pressure: An evaluation of three methods of expression
43. A comparison of recombinant urokinase with vascular surgery as initial treatment for acute arterial occlusion of the legs
44. The value of non-invasive techniques for the assessment of critical limb ischaemia
45. Relationship between transcutaneous oxygen tension, ankle blood pressure, and clinical outcome of vascular surgery in diabetic and nondiabetic patients
46. Transcutaneous oxygen (TcPO2) estimates probability of healing in the ischemic extremity
47. Peripheral arterial disease: Gadolinium-enhanced MR angiography versus color-guided duplex US-a meta-analysis
48. Prevention of venous thromboembolism
49. Collaborative overview of randomized trials of antiplatelet therapy: I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of disease
50. Pentoxifylline efficacy in the treatment of intermittent claudication: Multicenter controlled double-blind trial with objective assessment in chronic occlusive arterial disease patients
51. Conservative drug treatment in patients with moderately severe chronic occlusive peripheral arterial disease
52. Naftidrofuryl in chronic arterial disease: Results of a six month controlled multicenter study using Naftidrofuryl tablets 200 mg
53. Naftidrofuryl in chronic arterial disease: Results of a controlled multicenter study
54. Buflomedil in arterial occlusive disease: Results of a controlled multicentre study
55. A new pharmacological treatment for intermittent claudication: Results of a randomized, multicenter trial
56. Intravenöse prostaglandin E1-therapie bei patienten mit peripherer arterieller verschlusskrankheit (AVK) im stadium III: Eine doppelblinde, placedo-kontrollierte studie
57. Treatment of limb threatening ischemia with intravenous Iloprost: A randomised double-blind placebo controlled study
58. Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb
59. 165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia
60. Lower-extremity edema associated with gene transfer of naked DNA encoding vascular endothelial growth factor
61. VEGF gene delivery to myocardium: Deleterious effects of unregulated expression
62. Adjunctive systemic hyperbaric oxygen therapy in treatment of severe prevalently ischemic diabetic foot ulcer: A randomised study
63. Is hyperbaric oxygen a useful adjunct in the management of problem lower extremity wounds?
64. Limitations of hyperbaric oxygenation in occlusive arterial disease
65. Management of acute lower extremity arterial ischemia due to embolism and thrombosis
66. Anticoagulant treatment during and after embolectomy
67. Factors that affect the outcome of peripheral arterial embolization
68. Acute peripheral arterial occlusion: Predictors of success in catheter-directed thrombolytic therapy
69. Results of a prospective randomized trial evaluating surgery versus thrombolysis for ischemia of the lower extremity: The STILE trial
70. Thrombolysis as the initial treatment for acute lower limb ischemia
71. Optimal methods of aortoiliac reconstruction
72. Six-year prospective multicenter randomized comparison of autologous saphenous vein and expanded polytetrafluoroethylene grafts in infrainguinal arterial reconstructions
73. Present status of reversed vein bypass grafting: Five-year results of modern series
74. Infrainguinal arterial reconstruction with nonreversed greater saphenous vein
75. Antithrombotic therapy in peripheral arterial occlusive disease
76. Warfarin improves the outcome of infrainguinal vein bypass grafting at high risk for failure
77. Efficacy of oral anticoagulation compared with aspirin after infrainguinal bypass surgery (The Dutch Bypass Oral Anticoagulants or Aspirin Study): A randomised trial
78. Transluminal treatment of arteriosclerotic obstruction: Description of a new technique and a preliminary report of its application
79. Meta-analysis of the results of percutaneous transluminal angioplasty and stent placement for aortoiliac occlusive disease
80. Primary stent placement for chronic iliac artery occlusions: Follow-up results in 103 patients
81. Acute limb ischemia due to arterial embolism or thrombosis: Influence of limb ischemia versus pre-existing cardiac disease on postoperative mortality rate
82. Thrombolysis of peripheral arterial and graft occlusions: Improved results using high-dose urokinase
83. Thrombolytic therapy with use of alteplase (rt-PA) in peripheral arterial occlusive disease: Review of the clinical literature. The Advisory Panel
84. Reteplase in the treatment of peripheral arterial and venous occlusions: A pilot study
85. A comparison of thrombolytic therapy with operative revascularization in the initial treatment of acute peripheral arterial ischemia
86. Randomised comparison of primary stent placement versus primary angioplasty followed by selective stent placement in patients with iliac-artery occlusive disease
87. Aortic and iliac stenoses: Follow-up results of stent placement after insufficient balloon angioplasty in 118 cases
88. Multicenter trial of the Wallstent in iliac and femoral arteries
89. Palmaz stent placement in iliac and femoropopliteal arteries: Primary and secondary patency in 310 patients with two to four year follow-up
90. Percutaneous revascularization of complete iliac artery stenoses and occlusions with the use of Wallstent: Three-year experience
91. Femoropopliteal angioplasty in patients with claudication: Primary and secondary patency in 140 limbs with one to three year follow-up
92. Long-segment (> or = 10 cm) femoropopliteal angioplasty: Improved technical success and long-term patency
93. Femoropopliteal artery stent placement: Evaluation of long-term success
94. Limitations of percutaneous transluminal angioplasty with stenting for femoropopliteal arterial occlusive disease
95. Strecker stents in the femoropopliteal arteries: Value of duplex ultrasonography in restenosis assessment
96. Early outcome and intermediate follow-up of vascular stents in the femoral and popliteal arteries without long-term anticoagulation